December 4th – Albert Bourla, CEO of Pfizer, said on the 3rd local time that it is still unclear whether people who are vaccinated against Pfizer can still spread the virus.
Burla told NBC that whether the novel coronavirus will spread after vaccination is still a matter of long-term observation. He is not aware of it at present. Burla said he believed that participants who had only received placebo vaccine trials would also be vaccinated.
Burla said: “This is a moral and ethical dilemma and obligation. I believe that in discussions with regulators, we should find a way, rather than vaccinated all placebo participants sooner or later.”
According to the report, Pfizer has asked the U.S. Food and Drug Administration (FDA) for emergency use authorization for its vaccine. FDA advisers will meet on December 10th local time to discuss the application.
In addition, a spokesman for the British Ministry of Health and Social Health said on the 2nd that the government has accepted the recommendation of the Drug and Medical Products Regulatory Authority to approve the use of the coronavirus vaccine of Pfizer and BioNTech.
The vaccine will be available throughout the UK from next week, making the first country in the world to approve the use of the vaccine.
However, Dr. Paul Offit, director of the Vaccine Education Center of Children’s Hospital in Philadelphia and a member of the FDA Vaccine Advisory Committee, said that there are still many unresolved problems with the vaccine.
“We need to answer a million questions to ensure we know exactly how safe and effective the vaccine is,” Orfitt said.
- Does this vaccine work for people over 65 years old ?
- Is it equally effective in different racial and ethnic groups ?
- Does it work for people with various diseases ?
In early November, Pfizer said that the results of large-scale research showed that Pfizer’s coronavirus vaccine prevented 90% of coronavirus infections.
In several subsequent releases in January, Pfizer adjusted its COVID-19 vaccine effectiveness to 95% and said that it had met the requirements for emergency use authorization and would submit an application to the regulator within a few days.
However, a new technology such as Pfizer’s coronavirus vaccine has never been used in mass human vaccination before. Experts warned that little is known about its security, effective time and beneficiary base.
